SU-9516
CAS No. 377090-84-1
SU-9516( SU9516 | SU 9516 )
Catalog No. M14301 CAS No. 377090-84-1
A selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
A selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 39 | In Stock |
|
5MG | 60 | In Stock |
|
10MG | 95 | In Stock |
|
25MG | 197 | In Stock |
|
50MG | 356 | In Stock |
|
100MG | 530 | In Stock |
|
500MG | 1152 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU-9516
-
NoteResearch use only, not for human use.
-
Brief DescriptionA selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
-
DescriptionA selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
-
In VitroSU9516 shows slight activities against PKC, p38, PDGFr and EGFR, with IC50 of >10, >10, 18, and >100 μM. SU9516 (5 μM) decreases cdk2-specific Phosphorylation of pRB and inhibits cell cycle progression in RKO cells. SU9516 (5 μM) also induces apoptosis in RKO and SW480 Cells. SU9516 (5 μM) results in enhanced pRb/E2F complex formation in HT-29 cells. SU9516 enhances presence of E2F species in multiprotein complexes. SU9516 (5 μM) rapidly induces cytochrome crelease, Bax mitochondrial translocation, and apoptosis in association with pronounced down-regulation of the antiapoptotic protein Mcl-1. SU9516 causes down-regulation of Mcl-1 mRNA levels in human leukemia cells. Furthermore, SU9516 treatment results in a marked increase in reactive oxygen species production.
-
In Vivo——
-
SynonymsSU9516 | SU 9516
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK1|CDK2|CDK4|p38|PKC
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number377090-84-1
-
Formula Weight241.2453
-
Molecular FormulaC13H11N3O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C1NC2=C(C=C(OC)C=C2)/C1=C/C3=CN=CN3
-
Chemical Name2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-5-ylmethylene)-5-methoxy-, (3Z)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lane ME, et al. Cancer Res. 2001 Aug 15;61(16):6170-7.
2. Gao N, et al. Mol Pharmacol. 2006 Aug;70(2):645-55.
3. Sarathy A, et al. Mol Ther. 2017 Apr 5. pii: S1525-0016(17)30121-1.
molnova catalog
related products
-
BQU57
BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth.
-
Ribociclib succinate
Ribociclib succinate is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex.
-
CK7
CK7, a?Cdk2/9?inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.